SciSparc Ltd. has announced the publication of a Japanese divisional patent for a novel pharmaceutical combination of paracetamol and palmitoylethanolamide $(PEA.AU)$. This innovative combination is designed to enhance pain and fever relief with lower doses and fewer side effects compared to paracetamol alone. By potentially offering a safer and more effective treatment option, the drug candidate aims to minimize risks like liver damage while improving outcomes for various types of pain and fever, marking a significant advancement in pain management.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。